Matrix metalloproteinase 3 restricts viral infection by enhancing host antiviral immunity.


Journal

Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699

Informations de publication

Date de publication:
10 2022
Historique:
received: 12 05 2022
revised: 14 07 2022
accepted: 01 08 2022
pubmed: 9 8 2022
medline: 9 9 2022
entrez: 8 8 2022
Statut: ppublish

Résumé

Viral pandemics pose great threats to human health and the economy. The host evolved a complex immune response against viral infection. Matrix metalloproteinase 3 (MMP3), also known as stromelysin-1, has an emerging role in immune regulation during pathogen infection. Using in vitro and in vivo infection models, we showed that MMP3 exhibits broad-spectrum antiviral activities against vesicular stomatitis virus (VSV), influenza A virus (H1N1) and human herpes virus 1 (HSV-1). MMP3 deficient mice are susceptible to viral infection and display a compromised antiviral immune response. Correspondingly, the mice with MMP3 overexpression are resistant to viral infection. The mechanistic study suggested that MMP3 is translocated from the cytoplasm into the cell nucleus upon virus infection and influence NF-κB activities, thus amplifying antiviral immune responses. This study suggested a novel function of MMP3 in viral infection and provided new ideas for developing antiviral drugs based on modulating MMP activity.

Identifiants

pubmed: 35940311
pii: S0166-3542(22)00157-7
doi: 10.1016/j.antiviral.2022.105388
pii:
doi:

Substances chimiques

Antiviral Agents 0
Matrix Metalloproteinase 3 EC 3.4.24.17
Mmp3 protein, mouse EC 3.4.24.17

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105388

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Tingting Feng (T)

Department of Respiratory Medicine, Children's Hospital of Soochow University, Soochow University, Suzhou, China; Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China. Electronic address: ttfeng@suda.edu.cn.

Hao Tong (H)

Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China. Electronic address: touch42@163.com.

Zhihao Ming (Z)

Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China. Electronic address: zhihaoming8@163.com.

Lei Deng (L)

Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China. Electronic address: dengleistory@163.com.

Jiayan Liu (J)

Department of Radiology, Dushu Lake Hospital Affiliated to Soochow University, Suzhou, China. Electronic address: 13147701959@163.com.

Jiahui Wu (J)

Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China. Electronic address: 1830401145@stu.suda.edu.cn.

Zhengrong Chen (Z)

Department of Respiratory Medicine, Children's Hospital of Soochow University, Soochow University, Suzhou, China. Electronic address: chen_zheng_rong@163.com.

Yongdong Yan (Y)

Department of Respiratory Medicine, Children's Hospital of Soochow University, Soochow University, Suzhou, China. Electronic address: yyd3060@126.com.

Jianfeng Dai (J)

Institutes of Biology and Medical Sciences, Jiangsu Key Laboratory of Infection and Immunity, Soochow University, Suzhou, China. Electronic address: daijianfeng@suda.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH